A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer or Malignant Peritoneal Mesothelioma

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 18 → 32 participants
    • Trial arms changed: 1 → 2
    • Eligibility criteria expanded, about 67 words
    • Study title expanded, about 4 words
  2. 5 versions Re-verified since Apr 17, 2025, no change to tracked fieldsv4-v8
  3. Eligibility criteria expanded, about 2 wordsv3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Memorial Sloan Kettering Cancer Center
785 trials monitored
See 116 trials at risk
Breast Cancer
5,486 trials monitored
See 312 trials at risk
Diabetes
5,141 trials monitored
See 246 trials at risk
Gastric Cancer
1,286 trials monitored
See 61 trials at risk
and 1 more disease
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.
Trial Details
NCT Number NCT06623396
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions
(from sponsor)		 Mesothelin Positive, Mesothelin-Expressing Tumors, Esophageal Adenocarcinoma, Esophageal Adenocarcinomas, Esophagogastric Adenocarcinoma, Peritoneal Carcinomatosis, Breast Neoplasms, Diabetes Mellitus
Related terms Adenocarcinoma Of Esophagus, Breast Neoplasms, Diabetes Mellitus, Peritoneal Neoplasms
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov